After speedrunning a series of major manufacturing milestones in the past year and a half, the “biotech floodgates” have ...
With an increasingly promising roster of approved cell therapies still burdened by complex manufacturing, multiple companies have emerged in recent years on a mission to simplify production for the ...
It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...
Pascal Touchon serves as global strategy advisor to RoslinCT and board director, bringing over four decades of international experience in the biopharmaceutical industry, combining operational ...
Officials at Mytos, which is automating cell manufacturing, launched its automated contract development and manufacturing organization (CDMO), offering to overcome one of what they call regenerative ...
The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...
CCRM and its CDMO subsidiary OmniaBio Inc., today announced an agreement with Avectas Limited ("Avectas") to evaluate its automated, integrated and scalable cell therapy manufacturing platform. The ...
TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...
Cause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study Healthy volunteers were recruited and underwent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results